Owlstone Medical protects investments with cystic fibrosis

Sowstone Medical (“Owlstone”), a global leader in Breath biopsy^® In the case of applications in early detection of diseases and precision medicine, today it has announced that the Cystic Foundation Foundation Foundation has made USD 2.3 million (about 1.7 million pounds) in Olstone in order to develop a breathing test (PA) detection (PA) in patients with cystic fibrosis (CF).

The purpose of the investment is to develop a respiratory test suitable both for early detection of a new PA infection and monitoring chronic infection in patients with CF, with diagnostic accuracy at least comparable to sputum breeding tests. Using the specialist knowledge of OWLSTONE in the analysis of volatile organic compounds (VOC), the test will also be developed to distinguish PA from S. Aureus and other common respiratory bacterial pathogens found in the lungs of people from CF.

Initial work focuses on chronic PA to determine the scientific proof that LZO can identify this lung infection for breath and be used as part of long -term monitoring of infection. If it succeeds, you can organize additional work to test the ability of this approach to detect new PAW infections – an important event in the clinical care of people with CF.

CF is a progressive genetic disorder affecting over 105,000 people around the world. Characterized by excessive mucus production, which stops pathogens in the lungs, CF causes severe lung infections and can lead to respiratory failure. PA, which affects about 25% of patients with CF, is a significant threat to people with CF. After determining in the lungs, it is very difficult to eliminate, which means that early detection and aggressive treatment of infection are critical.

PA is usually detected by sputum culture; However, this is difficult to make in many children and is becoming more and more difficult in adults with CF due to the beneficial effects of other therapies that reduce the mucus of the respiratory tract, and thus the ability to ensure a proper sample of sputum.

. ”

Billy Boyle, co -founder and general director, Owlstone Medical

He added: